A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease.

Biological response modifiers such as interleukin 2 (IL2) may be most effective in the setting of minimal residual disease. In a phase I-II clinical trial, IL2 was administered to 10 patients in remission of acute myeloid leukaemia and three with multiple myeloma 1-4 weeks after treatment with ablat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottlieb, D. J., Brenner, M. K., Heslop, H. E., Bianchi, A. C., Bello-Fernandez, C., Mehta, A. B., Newland, A. C., Galazka, A. R., Scott, E. M., Hoffbrand, A. V.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247111/
https://www.ncbi.nlm.nih.gov/pubmed/2803933

Ejemplares similares

Ejemplares similares